SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow of -$1.67M in Q1 FY2026
Q1 FY2026 investing cash flow was -$1.67M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (11.79M) USD
- Year-over-year change
- —
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.79M) | — |
Investing Cash Flow vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $928.77M USD | -32.1% | -10.3% | 8.5% | |
| LTM Jun 2026 | $463.16M USD | -4.9% | +28.4% | 8.7% | |
| LTM Mar 2026 | $88.11M USD | +143.9% | — | 1157.0% | |
| LTM Mar 2026 | CHF 35.56M CHF | -46.9% | +155.8% | 7055.6% | |
| LTM Jun 2026 | $14.69M USD | -4.5% | — | 2.4% | |
| LTM Mar 2026 | $14.61M USD | +392.5% | +47.3% | 28.1% | |
| LTM Apr 2026 | $13.14M USD | +132.8% | — | 4.5% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $11.79M USD | — | — | — |
| LTM Mar 2026 | $4.88M USD | +104.8% | -24.9% | 3.8% | |
| LTM Mar 2026 | $284K USD | +6.0% | -38.6% | 0.4% | |
| Peer median (excluding SGP) | — | +6.0% | +9.0% | 8.5% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Net Income | (39.87M) |
| Depreciation & Amortization | 612K |
| Deferred Income Tax | 0 |
| Stock-Based Compensation | 2.79M |
| Change in Working Capital | 2.45M |
| Accounts Receivables | (8K) |
| Inventory | 0 |
| Accounts Payables | 549K |
| Other Working Capital | 1.91M |
| Other Non-Cash Items | 1.32M |
| Operating Cash Flow | (32.7M) |
| Capital Expenditures | (789K) |
| Acquisitions (Net) | 0 |
| Purchases of Investments | (17M) |
| Sales of Investments | 6M |
| Other Investing Activities | 0 |
| Investing Cash Flow | (11.79M) |
| Debt Repayment | 0 |
| Common Stock Issued | 170K |
| Common Stock Repurchased | (1.45M) |
| Dividends Paid | 0 |
| Other Financing Activities | (1.47M) |
| Financing Cash Flow | 124.59M |
| Effect of Forex Changes | 0 |
| Net Change in Cash | 80.09M |
| Free Cash Flow | (33.49M) |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.